CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients

Summary

This Phase II study is to evaluate the efficacy and safety of a CD19-targeting humanized selective CAR-T (CD19 hsCAR-T) in refractory/relapsed CD19+ B-ALL leukemia patients who have no available curative treatment options, have a limited prognosis with currently available treatments, and were previously treated with a B cell directed cell therapy.

Timeline

Start

2019-04-22

Primary completion

2021-12-31

Completion

2023-12-21

Drugs

Indications